(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 88.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Immunome's revenue in 2025 is $9,041,000.On average, 1 Wall Street analysts forecast IMNM's revenue for 2025 to be $793,859,480, with the lowest IMNM revenue forecast at $793,859,480, and the highest IMNM revenue forecast at $793,859,480. On average, 3 Wall Street analysts forecast IMNM's revenue for 2026 to be $2,388,534,493, with the lowest IMNM revenue forecast at $338,238,048, and the highest IMNM revenue forecast at $4,514,478,008.
In 2027, IMNM is forecast to generate $5,460,761,986 in revenue, with the lowest revenue forecast at $4,086,680,785 and the highest revenue forecast at $7,677,742,837.